Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) could be just weeks away from having the first approved therapy, after UCB's Kygevi was recommended by the EMA's human ...

UCB has announced that its Kygevi (doxecitine and doxribtimine) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

The clinical program for the first TK2d therapy reveals barriers to drug development for ultrarare diseases—and possible routes around them. In November 2025, doxecitine and doxribtimine (Kygevvi ®) ...

UCB, a global biopharmaceutical company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...

Kygevvi, a combination of doxecitine and doxribtimine, is recommended by the EMA for TK2d treatment in young patients. The treatment addresses genetic pathology by supplementing deoxypyrimidine ...

At its January meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of Kygevvi ...

In the latest bunch of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), Novo Nordisk’s semaglutide for severe liver disease could be soon off ...

Which of the statements below about the prognosis for thymidine kinase 2 deficiency (TK2d) are correct? Select one of the options for each question, then submit your answers to see how well you scored ...

Thymidine kinase 2 deficiency (TK2d) is a very rare genetic disease that causes muscle weakness, which can happen in different parts of your body. TK2d can sometimes be severe and affect your ability ...

"The approval of doxecitine and doxribtimine represents a pivotal moment for the TK2d community who previously had no FDA-approved treatment options for this rare genetic mitochondrial disease beyond ...